missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Lonza™ Clonetics™ Endothelial Cell Growth Medium BulletKit-2-MV
Click to view available options
Quantity:
1 Kit
Unit Size:
Each
Description
- EGM™-2MV
- Microvascular Endothelial Cell Growth Medium-2 BulletKit™
Order Info
dimProductType

Specifications
Specifications
Product Type | Growth Medium |
Quantity | 1 Kit |
Content And Storage | No BBE (bovine brain extract), hEGF, hydrocortisone, GA-1000 (Gentamicin, Amphotericin-B), FBS (fetal bovine serum) 25 ml, VEGF, hFGF-B, R3, -IGF-1, ascorbic acid |
Safety and Handling



Product Identifier
- EGM-2 MV Endothel Med BulletKit
- Danger
- Serious eye damage/eye irritation Category 2
- Flammable liquid Category 2
- Respiratory sensitiser Category 1
- Skin sensitiser Category 1
- H225-Highly flammable liquid and vapour.
- H317-May cause an allergic skin reaction.
- H319-Causes serious eye irritation.
- H334-May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- P210-Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
- P233-Keep container tightly closed.
- P261-Avoid breathing dust/fume/gas/mist/vapours/spray.
- P280-Wear protective gloves/protective clothing/eye protection/face protection.
- P284-¢In case of inadequate ventilation! wear respiratory protection.
- P303+P361+P353-IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/ shower.
- P304+P340-IF INHALED: Remove person to fresh air and keep comfortable for breathing.
- P333+P313-If skin irritation or rash occurs: Get medical advice/attention.
- P337+P313-If eye irritation persists: Get medical advice/attention.
- P342+P311-If experiencing respiratory symptoms: Call a POISON CENTER/doctor/ .
- P370+P378-In case of fire: Use to extinguish.
- MIXTURE LIST-Contains : ethanol, gentamycinsulphate
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction